Company News

Share this article:

Gilead Sciences Inc. has agreed to pay $1.4 billion, or $20 a share, for CV Therapeutics, a manufacturer of chest pain and heart drugs. The bid tops Astellas' $16-a-share bid for CV Therapeutics, announced last January.

 

GSW Worldwide's Pink Tank, an agency specializing in health marketing to women, has launched a new web site: www.knowher.com. The site provides information about strategic consulting services for clients who want to reach women consumers.

Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Massachusetts painkiller ban overruled

A District Court says Massachusetts cannot ban opioid painkiller Zohydro.

Ranbaxy extends branded Diovan's life

Ranbaxy may be on the blocks, but it has a hold on the right to produce generics of the Novartis heart medication Diovan. Only problem: it can't, and that is good news for Novartis.

FDA approves Glaxo's GLP-1

Type-2 diabetes injection Tanzeum, also known as albiglutide, scored the approval Tuesday.